Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 895.9 INR 0.81% Market Closed
Market Cap: 141.9B INR

Intrinsic Value

The intrinsic value of one JUBLPHARMA stock under the Base Case scenario is 864.85 INR. Compared to the current market price of 895.9 INR, Jubilant Pharmova Ltd is Overvalued by 3%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

JUBLPHARMA Intrinsic Value
864.85 INR
Overvaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Jubilant Pharmova Ltd

JUBLPHARMA
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for JUBLPHARMA cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Jubilant Pharmova Ltd
NSE:JUBLPHARMA
IN
Pharmaceuticals
Market Cap
141.9B INR
IPO
Nov 9, 1994
IN
Pharmaceuticals
Market Cap
141.9B INR
IPO
Nov 9, 1994
Price
â‚ąfalse
EPS
â‚ąfalse
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about JUBLPHARMA?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Jubilant Pharmova Ltd
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Jubilant Pharmova Ltd

Current Assets 35B
Cash & Short-Term Investments 12.9B
Receivables 8.3B
Other Current Assets 13.8B
Non-Current Assets 84.2B
Long-Term Investments 631m
PP&E 42.7B
Intangibles 35.5B
Other Non-Current Assets 5.4B
Efficiency

Free Cash Flow Analysis
Jubilant Pharmova Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Jubilant Pharmova Ltd

Revenue
70.6B INR
Cost of Revenue
-22.2B INR
Gross Profit
48.5B INR
Operating Expenses
-41.2B INR
Operating Income
7.3B INR
Other Expenses
-981m INR
Net Income
6.3B INR
Fundamental Scores

JUBLPHARMA Profitability Score
Profitability Due Diligence

Jubilant Pharmova Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
51/100
Profitability
Score

Jubilant Pharmova Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

JUBLPHARMA Solvency Score
Solvency Due Diligence

Jubilant Pharmova Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
51/100
Solvency
Score

Jubilant Pharmova Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

JUBLPHARMA Price Targets Summary
Jubilant Pharmova Ltd

Wall Street analysts forecast JUBLPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JUBLPHARMA is 1 336.2 INR with a low forecast of 1 247.35 INR and a high forecast of 1 454.25 INR.

Lowest
Price Target
1 247.35 INR
39% Upside
Average
Price Target
1 336.2 INR
49% Upside
Highest
Price Target
1 454.25 INR
62% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for JUBLPHARMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

JUBLPHARMA Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one JUBLPHARMA stock?

The intrinsic value of one JUBLPHARMA stock under the Base Case scenario is 864.85 INR.

Is JUBLPHARMA stock undervalued or overvalued?

Compared to the current market price of 895.9 INR, Jubilant Pharmova Ltd is Overvalued by 3%.

Back to Top